English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Current coronary heart disease ( CHD ) risk assessments inadequately assess intermediate‐risk patients, leaving many undertreated and vulnerable to heart attacks. A novel  CHD  risk‐assessment ( CHDRA ) tool was developed for intermediate‐risk stratification using biomarkers and established risk factors to significantly improve  CHD  risk discrimination.    Hypothesis  Physicians will change their treatment plan in response to more information about a patient's  CHD  risk level provided by the  CHDRA  test.    Methods  A Web‐based survey of cardiology, internal medicine, family practice, and obstetrics/gynecology physicians (n = 206) was conducted to assess the  CHDRA  clinical impact. Each physician was shown 3 clinical vignettes representing community‐based cohort participants randomly selected from 8 total vignettes. For each, the physicians assessed the individual's  CHD  risk and selected preferred therapies based on the individual's comorbidities, physical examination, and laboratory results. The individual's  CHDRA  score was then provided and the physicians were queried for changes to their initial treatment plans.    Results  After obtaining the  CHDRA  result, 70% of the physician responses indicated a change to the patient's treatment plan. The revised lipid‐management plans agreed more often (74.6% of the time) with the current Adult Treatment Panel  III  guidelines than did the original plans (57.6% of the time). Most physicians (71.3%) agreed with the statement that the  CHDRA  result provided information that would impact their current treatment decisions.    Conclusions  The  CHDRA  test provided additional information to which physicians responded by more often applying appropriate therapy and actions aligned with guidelines, thus demonstrating the clinical utility of the test.

Clinical Utility of a Novel Coronary Heart Disease Risk‐Assessment Test to Further Classify Intermediate‐Risk Patients